CD276 and neoplasm: However, in preclinical studies which used B7-H3 as therapeutic target including B7-H3-targeting chimeric antigen receptor (CAR) T cells, significant anti-tumor effects in preclinical models (23, 26, 27, 60, 61), but no toxicity was observed, likely due to profoundly lower B7-H3 antigen levels in healthy tissue (27).